Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignanciesLund, Sweden, January 29, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces the publication of the results from a clinical phase I first-in-human study of the CD40 agonistic antibody ADC-1013 (JNJ-64457107). The top line data from this study was presented at the Society for Immunotherapy of Cancer (SITC) in November 2017. The results show that the agonistic anti-CD40 antibody ADC-1013 is safe and tolerated at clinically relevant dose levels.